Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1558-822X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment ; day:22 ; month:2 ; year:2016 ; pages:1-9
Current hematologic malignancy reports ; (22.2.2016), 1-9
- Urheber
-
Nishihori, Taiga
- Beteiligte Personen und Organisationen
-
Song, Jinming
Shain, Kenneth H.
SpringerLink (Online service)
- DOI
-
10.1007/s11899-016-0308-3
- URN
-
urn:nbn:de:1111-201602231389
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Nishihori, Taiga
- Song, Jinming
- Shain, Kenneth H.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Minimal residual disease in multiple myeloma: current status
Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions
Personalized immunoglobulin aptamers for detection of multiple myeloma minimal residual disease in serum
Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma
The role of minimal residual disease and serum free light chain ratio in the management of multiple myeloma
Measurable residual disease in multiple myeloma: ready for clinical practice?
High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes
Imaging of treatment response and minimal residual disease in multiple myeloma: state of the art WB-MRI and PET/CT
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
Multiple myeloma
Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma
Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal-residual-disease detection in Chinese patients with multiple myeloma
Minimal residual disease in multiple myeloma: current status
Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions
Personalized immunoglobulin aptamers for detection of multiple myeloma minimal residual disease in serum
Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma
The role of minimal residual disease and serum free light chain ratio in the management of multiple myeloma
Measurable residual disease in multiple myeloma: ready for clinical practice?
High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes
Imaging of treatment response and minimal residual disease in multiple myeloma: state of the art WB-MRI and PET/CT
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
Multiple myeloma
Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma
Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal-residual-disease detection in Chinese patients with multiple myeloma
Minimal residual disease in multiple myeloma: current status
Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions
Personalized immunoglobulin aptamers for detection of multiple myeloma minimal residual disease in serum
Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma
The role of minimal residual disease and serum free light chain ratio in the management of multiple myeloma
Measurable residual disease in multiple myeloma: ready for clinical practice?
High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes
Imaging of treatment response and minimal residual disease in multiple myeloma: state of the art WB-MRI and PET/CT
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
Multiple myeloma
Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma